Natera Announces Positive Results From IMvigor011 Phase III Study In Muscle-Invasive Bladder Cancer
Cell-free DNA testing company Natera, Inc. (NTRA) announced Friday an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris, France.